课题基金 / 基金详情

Function of the p53-induced lncRNA LINC01021 in suppression of colorectal cancer

Function of the p53-induced lncRNA LINC01021 in suppression of colorectal cancer
p53诱导的lncRNA LINC01021在抑制结直肠癌中的功能
批准号:
490846707
负责人:
Professor Dr. Heiko Hermeking
金额:
$0.0万
依托单位:
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
--
资助国家:
德国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Professor Dr. Heiko Hermeking的其他基金

相似基金

相关文献

中文摘要
翻译
最近的测序分析显示,人类基因组编码大约32000个长链非编码/ lncrna。因此,这类转录本在数量上与蛋白质编码mrna相似,但在很大程度上代表了未知的领域,有望在介导肿瘤抑制中发挥重要作用。lncRNA结构或调控的改变可能与人类肿瘤的发病机制有关。LncRNAs的长度超过200个核苷酸,具有多种功能,主要在细胞核内结合并影响染色质相关蛋白调节基因表达,但LncRNAs也与其他rna相互作用,如microRNAs和DNA。值得注意的是,由最常见突变的肿瘤抑制基因编码的p53转录因子也调节lncrna。然而,p53调控的lncrna的表征和鉴定还远未完成。结直肠癌(CRC)中约60%的病例显示p53突变。为了全面研究p53在CRC中的功能,我们最近使用RNA- seq、miR-Seq和定量蛋白质组学(pSILAC)分析了SW480 CRC细胞中条件p53等位基因激活后的差异RNA、microRNA和蛋白质表达。此外,我们通过ChIP-Seq分析确定了p53的整体DNA结合模式。通过这些分析的结合,我们确定了LINC01021是一种新的p53诱导的lincRNA,当其异位表达时,可重复地显示出p53 (>600x)的显著诱导和抑制增殖。最近,我们报道了LINC01021的缺失增加了CRC细胞系对化疗药物的敏感性。此外,在CRC患者的CMS4亚群中,LINC01021的低表达与较差的生存率相关。尽管LINC01021具有肿瘤相关能力,但其作用的分子机制仍知之甚少。我们的初步结果表明,LINC01021调节了p53调控基因的一个子集的表达。在这里,我们打算使用基因组和蛋白质组范围内,公正的方法来揭示LINC01021参与p53网络调节的分子机制。为了确定LINC0121影响基因表达的分子机制,我们将通过RNA下拉和质谱分析鉴定LINC01021的蛋白相互作用伙伴。我们将进一步详细描述LINC01021相互作用蛋白及其在LINC01021介导的基因调控中的功能作用。linc01021介导的基因调控将通过ChIRP(染色质分离RNA纯化)-Seq分析来鉴定。将确定linc01021调控基因的功能相关性及其与p53介导的肿瘤抑制蛋白的相互作用。综上所述,这些分析旨在阐明LINC01021在p53网络中发挥关键功能的机制。
英文摘要
Recent sequencing analyses revealed that the human genome encodes approximately 32.000 long-non-coding/lncRNAs. Therefore, this class of transcripts is similar in number as protein-coding mRNAs, but represents largely uncharted territory, which promises to have important functions in mediating tumor suppression. Alterations in lncRNA structure or regulation presumably contribute to the pathogenesis of human tumors. LncRNAs have a length of more than 200 nucleotides and fulfil diverse functions, mainly in the nucleus where they bind and affect chromatin-associated proteins to regulate gene expression, but LncRNAs also interact with other RNAs, e.g. microRNAs, and DNA. Notably, also the p53 transcription factor, which is encoded by the most commonly mutated tumor suppressor gene, regulates lncRNAs. However, the characterization and identification of p53-regulated lncRNAs is far from complete. Colorectal cancers (CRC) display p53 mutations in ca. 60% of all cases. In order to comprehensively study the function of p53 in CRC we recently determined the differential RNA, microRNA and protein expression after activation of a conditional p53 allele in SW480 CRC cells using RNA-Seq, miR-Seq and quantitative proteomics (pSILAC) analyses. In addition, we determined the global DNA binding pattern of p53 by a ChIP-Seq analysis. By the combination of these analyses, we identified LINC01021 as a novel p53-induced lincRNA, which reproducibly showed a dramatic induction by p53 (>600x) and suppressed proliferation, when expressed ectopically. More recently, we reported that deletion of LINC01021 increases sensitivity of CRC cell lines to chemotherapeutic drugs. Furthermore, in the CMS4 sub-set of CRC patients low expression of LINC01021 was associated with poor survival. Although, LINC01021 harbors tumor-relevant capacities the molecular mechanisms of its action are still poorly understood. Our preliminary results indicate that LINC01021 modulates the expression of a subset of p53-regulated genes. Here we intend to use genome- and proteome-wide, unbiased approaches to uncover the molecular mechanisms by which LINC01021 contributes to regulations within the p53 network. Protein interaction partners of LINC01021 will be identified by RNA pull-down and mass spectrometric analysis in order to determine the molecular mechanisms by which LINC0121 influences gene expression. The LINC01021 interacting proteins and their functional role in LINC01021-mediated gene regulation will be characterized in further detail. LINC01021-mediated gene regulations will be identified by ChIRP (chromatin isolation by RNA purification)-Seq analyses. The functional relevance of LINC01021-regulated genes and its interactions with proteins for p53-mediated tumor suppression will be determined. Taken together, these analyses aim to illuminate the mechanisms by which LINC01021 performs critical functions within the p53 network.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Analysis of the p53/HIF-1A/miR-34a pathway in colorectal cancer
  • 批准号:
    398348782
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    Professor Dr. Heiko Hermeking
  • 依托单位:
Analysis of the c-MYC-associated protein ZNF281
  • 批准号:
    119172693
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2009
  • 负责人:
    Professor Dr. Heiko Hermeking
  • 依托单位:
Genetic analysis of AP4 function in stem cells, tumor maintenance and metastasis formation
  • 批准号:
    106373515
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2009
  • 负责人:
    Professor Dr. Heiko Hermeking
  • 依托单位:
Analysis of organismal and tumor suppressive functions of 14-3sigma
  • 批准号:
    61990547
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2007
  • 负责人:
    Professor Dr. Heiko Hermeking
  • 依托单位:
国内基金
海外基金
Circ_0001313/miR-338-3p经P53调控铁死亡降低结直肠癌放化疗敏感性的机制
基于影像组学与代谢组学特征图谱的机器学习模型在P53突变型子宫内膜癌中的临床应用研究
  • 批准号:
    2026JJ82384
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    颜志鹏
  • 依托单位:
APR-246靶向突变p53通路逆转DLBCL耐药的分子功能及机制研究
  • 批准号:
    JCZRQNB202600696
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
黄芩素通过p53信号通路逆转胃黏膜肠上皮化生的机制研究